Obesity is associated with a higher risk of advanced prostate cancer, but men with the same body mass index (BMI) may differ in their underlying metabolic health. Using metabolomics data from nested case-control studies in the Health Professionals Follow-Up Study, we calculated Pearson correlations between 165 circulating metabolites and three adiposity measures (BMI, waist circumference, and derived fat mass from a validated prediction equation) to identify adiposity-associated metabolites. We used Lasso to further select metabolites for prediction models of adiposity measures, which we used to calculate metabolic scores representing metabolic obesity. In an independent set of 212 advanced prostate cancer cases (T3b/T4/N1/M1 or lethal during follow-up) and 212 controls, we used logistic regression to evaluate the associations between adiposity measures and metabolic scores with risk of advanced disease. All adiposity measures were associated with higher blood levels of carnitines (Pearson r range, 0.16 to 0.18) and lower levels of glutamine (r = -0.19) and glycine (r, -0.29 to -0.20), in addition to alterations in various lipids. No adiposity measure or metabolic score was associated with risk of advanced prostate cancer (e.g., odds ratio for a 5 kg/m2 increase in BMI 0.96 (95% CI: 0.73, 1.27) and BMI metabolic score 1.18 (95% CI: 0.57, 2.48)). BMI, waist circumference, and derived fat mass were associated with a broad range of metabolic alterations. Neither adiposity nor metabolic scores were associated with risk of advanced prostate cancer.

中文翻译：

---

卫生专业人员随访研究中肥胖和晚期前列腺癌风险的代谢组学分析。

肥胖与罹患晚期前列腺癌的风险较高相关，但是具有相同体重指数（BMI）的男性其潜在的代谢健康状况可能有所不同。使用来自Health Professionals跟进研究中嵌套病例对照研究的代谢组学数据，我们计算了165种循环代谢物与三种肥胖测量指标（BMI，腰围和从有效的预测方程式得出的脂肪量）之间的皮尔森相关性，以识别肥胖-相关代谢产物。我们使用Lasso进一步选择代谢物用于肥胖测量的预测模型，该模型用于计算代表代谢性肥胖的代谢评分。在一组独立的212例晚期前列腺癌病例（随访期间为T3b / T4 / N1 / M1或致死性）和212例对照中，我们使用逻辑回归来评估肥胖措施和代谢评分与晚期疾病风险之间的关联。除各种脂质的改变外，所有肥胖测量均与较高的血肉碱水平（Pearson r范围，0.16至0.18）和较低的谷氨酰胺水平（r = -0.19）和甘氨酸（r，-0.29至-0.20）相关。 。没有肥胖测量或代谢评分与晚期前列腺癌的风险相关（例如，BMI 0.96（95％CI：0.73，1.27）和BMI代谢评分1.18（95％CI：0.57， 2.48））。BMI，腰围和衍生脂肪量与广泛的代谢改变有关。肥胖和代谢评分均与晚期前列腺癌的风险无关。除各种脂质的改变外，所有肥胖测量均与较高的血肉碱水平（Pearson r范围，0.16至0.18）和较低的谷氨酰胺水平（r = -0.19）和甘氨酸（r，-0.29至-0.20）相关。 。没有肥胖测量或代谢评分与晚期前列腺癌的风险相关（例如，BMI 0.96（95％CI：0.73，1.27）和BMI代谢评分1.18（95％CI：0.57， 2.48））。BMI，腰围和衍生脂肪量与广泛的代谢改变有关。肥胖和代谢评分均与晚期前列腺癌的风险无关。除各种脂质的改变外，所有肥胖测量均与较高的血肉碱水平（Pearson r范围，0.16至0.18）和较低的谷氨酰胺水平（r = -0.19）和甘氨酸（r，-0.29至-0.20）相关。 。没有肥胖测量或代谢评分与晚期前列腺癌的风险相关（例如，BMI 0.96（95％CI：0.73，1.27）和BMI代谢评分1.18（95％CI：0.57， 2.48））。BMI，腰围和衍生脂肪量与广泛的代谢改变有关。肥胖和代谢评分均与晚期前列腺癌的风险无关。除了各种脂质的改变。没有肥胖测量或代谢评分与晚期前列腺癌的风险相关（例如，BMI 0.96（95％CI：0.73，1.27）和BMI代谢评分1.18（95％CI：0.57， 2.48））。BMI，腰围和衍生脂肪量与广泛的代谢改变有关。肥胖和代谢评分均与晚期前列腺癌的风险无关。除了各种脂质的改变。没有肥胖测量或代谢评分与晚期前列腺癌的风险相关（例如，BMI 0.96（95％CI：0.73，1.27）和BMI代谢评分1.18（95％CI：0.57， 2.48））。BMI，腰围和衍生脂肪量与广泛的代谢改变有关。肥胖和代谢评分均与晚期前列腺癌的风险无关。